Last $1.64 USD
Change Today 0.00 / 0.00%
Volume 6.7K
As of 8:10 PM 03/4/15 All times are local (Market data is delayed by at least 15 minutes).

casi pharmaceuticals inc (CASI) Snapshot

Open
$1.64
Previous Close
$1.64
Day High
$1.64
Day Low
$1.62
52 Week High
03/20/14 - $2.09
52 Week Low
12/18/14 - $1.07
Market Cap
53.2M
Average Volume 10 Days
8.9K
EPS TTM
$-0.47
Shares Outstanding
32.4M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for CASI PHARMACEUTICALS INC (CASI)

Related News

No related news articles were found.

casi pharmaceuticals inc (CASI) Related Businessweek News

No Related Businessweek News Found

casi pharmaceuticals inc (CASI) Details

CASI Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, develops therapeutics to treat cancer and other diseases primarily in the United States and China. The company’s lead drug candidate includes ENMD-2076, an Aurora A and angiogenic kinase inhibitor for the treatment of cancer, which has completed Phase I studies in patients with advanced solid tumors, multiple myeloma, and leukemia, as well as it is completing data for a multi-center Phase II study in patients with platinum resistant ovarian cancer. Its other product candidates in development include 2-methoxyestrdiol, an orally active compound for autoimmune diseases; and MKC-1, an orally-active cell cycle inhibitor that has completed Phase II clinical trials for cancer treatment. The company name was formerly known as EntreMed, Inc. and changed its name to CASI Pharmaceuticals, Inc. in June 2014. CASI Pharmaceuticals, Inc. was founded in 1991 and is headquartered in Rockville, Maryland.

15 Employees
Last Reported Date: 03/21/14
Founded in 1991

casi pharmaceuticals inc (CASI) Top Compensated Officers

Chief Executive Officer and Director
Total Annual Compensation: $285.2K
Principal Accounting Officer and Vice-Preside...
Total Annual Compensation: $175.1K
Chief Operating Officer, General Counsel and ...
Total Annual Compensation: $300.0K
Compensation as of Fiscal Year 2013.

casi pharmaceuticals inc (CASI) Key Developments

CASI Pharmaceuticals, Inc. Presents at 3rd Annual SACHS Cancer Bio Partnering and Investment Forum, Feb-23-2015 02:15 PM

CASI Pharmaceuticals, Inc. Presents at 3rd Annual SACHS Cancer Bio Partnering and Investment Forum, Feb-23-2015 02:15 PM. Venue: The New York Academy of Sciences, 7 World Trade Center, 250 Greenwich St, 40th Floor (D Elevator Bank), New York, NY10007, United States.

CASI Pharmaceuticals Announces Receipt Of Final Minutes From FDA Meeting Regarding Clinical And Regulatory Path Of ENMD-2076 For The Treatment Of Patients With Fibrolamellar Carcinoma (FLC)

CASI Pharmaceuticals, Inc. announced that it has received formal meeting minutes from the U.S. Food and Drug Administration (FDA) regarding the clinical and regulatory path leading to market approval of ENMD-2076 for the treatment of Fibrolamellar Carcinoma (FLC). The meeting minutes stem from a recent informative meeting between CASI and the FDA. The company plan to conduct a single arm trial to evaluate the overall response rate (ORR) of ENMD-2076 in FLC patients as the primary endpoint. The trial will be conducted as a Simon 2-stage study with interim futility analysis released after 16 patients reach a clinical endpoint. Futility would be declared if none of the patients experience a response and would result in the termination of the study. If, however, one or more patients experience a response according to the RECIST 1.1 criteria, the study would continue with additional patients. At that time, the company would expect to meet with the FDA to discuss what tumor response criteria would be considered reasonably likely to provide clinical benefit and support an accelerated approval based on the surrogate endpoint of tumor response. Assuming that the results of the proposed study show that ENMD-2076 improves overall tumor response, CASI would expect to propose a confirmatory clinical trial and, in parallel, submit an NDA under subpart H for accelerated approval of new drugs for serious or life-threatening illnesses based on overall tumor response rates. CASI will submit to the FDA a request for Breakthrough Therapy designation whenever clinical data meets the appropriate criteria.

CASI Pharmaceuticals, Inc. Seeks Acquisition

KEN REN, Chief Executive Officer of CASI Pharmaceuticals, Inc. (Nasdaq:CASI) states, "In 2015, we will further strengthen our management team by adding additional key talent for clinical and commercial development. We will also continue to acquire additional oncology drug candidates to further expand our product pipeline."

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
CASI:US $1.64 USD 0.00

CASI Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Allergan Inc/United States $235.68 USD +0.82
Novartis AG SFr.95.75 CHF +0.55
Regeneron Pharmaceuticals Inc $413.04 USD +0.54
View Industry Companies
 

Industry Analysis

CASI

Industry Average

Valuation CASI Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book 63.5x
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact CASI PHARMACEUTICALS INC, please visit www.casipharmaceuticals.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.